Hafrun Fridriksdottir
President, US and Global Head of R&D
Role: Hafrun joined Hikma in April 2024 as President of Hikma Rx. In 2025, Hafrun took on additional responsibilities leading Hikma’s new global R&D organisation and in February 2026, Hafrun was appointed as President, US, leading the Hikma Rx and commercial Injectables businesses in the US, in addition to her responsibilities as Global Head of R&D. Prior to joining Hikma, Hafrun held senior executive roles at leading global pharmaceutical companies including Alvotech, Teva Pharmaceuticals, Allergan and Actavis, and most recently has served in advisory and board roles for several biotech and mid-sized pharma companies.
Qualifications: MS Degree in Pharmacy and a PhD in Physical Pharmacy from the University of Iceland.
